Acer Therapeutics, NCATS to develop emetine as treatment for Covid-19

This article was originally published here

In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.

The post Acer Therapeutics, NCATS to develop emetine as treatment for Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply